PURE Bioscience (OTCMKTS:PURE – Get Free Report) released its earnings results on Monday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
PURE Bioscience Stock Performance
Shares of OTCMKTS PURE traded up $0.00 during trading hours on Monday, hitting $0.07. The stock had a trading volume of 1,425 shares, compared to its average volume of 34,526. The company has a market capitalization of $9.10 million, a P/E ratio of -2.33 and a beta of 0.16. The firm’s 50-day moving average price is $0.07 and its two-hundred day moving average price is $0.06. PURE Bioscience has a 52 week low of $0.04 and a 52 week high of $0.14.
About PURE Bioscience
PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.
PURE’s product suite includes concentrate formulations and ready-to-use solutions.
Read More
- Five stocks we like better than PURE Bioscience
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
